ROIV

ROIV

ROIV

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2025 Q3	Sep 30, 2025	Baron Health Care Fund	5.4%	-2.7%	ABBV, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, IMVT, INSM, IONS, ISRG, JNJ, LLY, MASI, PFE, RDNT, ROIV, SYK, TMO, UNH, WAT, XENE	AI, Biotechnology, GLP1, growth, healthcare, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The third quarter saw several positive biotechnology clinical data readouts, a strong rebound in biotechnology funding, and an acceleration in M&A activity.		View
2024 Q3	Sep 30, 2024	Peapack Private	-	-	ABBV, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, INSM, IONS, ISRG, JNJ, LLY, MASI, PFE, RDNT, ROIV, SYK, TMO, UNH, WAT, XENE	AI, Biotechnology, GLP-1, healthcare, M&A, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The quarter saw several positive biotechnology clinical data readouts, a strong rebound in biotechnology funding, and an acceleration in M&A activity.		View
2025 Q2	Aug 14, 2025	FPA Source Capital	6.7%	-	ABBV, ABT, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, IMVT, INSM, IONS, ISRG, JNJ, LLY, MASI, MDT, PFE, RDNT, ROIV, SYK, TMO, UNH, WAT, XEN.TO	AI, Biotechnology, GLP1, healthcare, Managed Care, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The quarter saw several positive biotechnology clinical data readouts, a strong rebound in biotechnology funding, and an acceleration in M&A activity.		View
2024 Q1	May 9, 2024	Greenlight Capital	1.1%	9.0%	BHF, CEIX, FHN, GRBK, HPQ, IMVT, KD, LBTYA, NYCB, PENN, ROIV, SOLB.BR, TECK, THC, VTSC.DE	AI, Copper, Long/Short, Macro, market structure, Passive investing, undervaluation, value	Greenlight established a position in HP Inc. to benefit from a potential AI-driven PC adoption cycle. Intel plans to release neural processing units this summer, and Microsoft is teasing AI features requiring NPUs. The firm believes AI optimism is not reflected in HPQ's share price.	LBTYA ROIV HPQ PENN SOLB.BR	View
2024 Q1	May 9, 2024	Tourlite Capital Management	4.5%	13.8%	ABUS, APG, ESPR, FIP, FTAI, LGND, OABI, PRGO, PRPL, ROIV	Biotechnology, Hedging, Idiosyncratic, Long/Short, spinoffs, value	Fund maintains four biotech long positions representing ~20% of gross long exposure, viewed as idiosyncratic opportunities based on litigation or corporate events rather than binary drug results. Positions include Roivant Sciences with significant cash position and share buyback program, Arbutus benefiting from Covid vaccine litigation, OmniAb spinoff with 300+ drugs in pipeline, and a recent spinoff trading at 65% discount to cash.	PRGO ROIV ESPR PRPL APG FTAI FIP	View
2025 Q1	May 23, 2025	Tourlite Capital Management	-4.6%	-4.6%	ABUS, COST, FIP, FTAI, GRAL, IMVT, NFE, OABI, ROIV, SOC, WMT	Biotech, consumer, energy, Event Driven, industrials, infrastructure, Long/Short, tariffs	The fund continues to see meaningful mispricing across select biotech companies, highlighting positions in Roivant, Arbutus, Immunovant, OmniAb, and Grail. Despite short-term volatility from macro headlines and policy developments, these companies trade at substantial discounts to intrinsic value, offering significant upside with a margin of safety over the long term.	FTAI FIP SOC	View
2025 Q1	Apr 4, 2025	Carrington Wealth Management	-	-	ABBV, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, INSM, IONS, ISRG, JNJ, LLY, MASI, RDNT, ROIV, SYK, TMO, UNH, WAT, XENE	AI, Biotechnology, GLP1, healthcare, M&A, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The quarter saw several positive biotechnology clinical data readouts, a strong rebound in biotechnology funding, and an acceleration in M&A activity.		View
2024 Q1	Apr 30, 2024	Penn Davis McFarland	-	-	IMVT, MRNA, PFE, ROIV	Biotechnology, Fed policy, inflation, M&A, monetary policy, Risk Appetite	The fund initiated a new position in Roivant, a biotech holding company that acquires orphaned drug candidates from big pharma and develops them through focused subsidiaries. The strategy has proven successful with recent asset sales like Televant to Roche for $7.1 billion. Immunovant represents the most valuable remaining subsidiary with potential for sale in the current heated biotech M&A environment.	ROIV	View
2026 Q1	Apr 28, 2026	Baron Health Care Fund	-7.0%	-7.0%	ACLX, ARGX, AZN, GH, JNJ, LLY, MRK, NTRA, RDNT, ROIV, TMO, WELL	AI, Biotechnology, Diagnostics, GLP1, healthcare, M&A, Pharmaceuticals			View
2025 Q1	Mar 31, 2025	EQUAM Global Value Fund	-1.2%	-1.2%	ABBV, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, IMVT, INSM, IONS, ISRG, JNJ, LLY, MASI, PFE, RDNT, ROIV, SYK, TMO, UNH, WAT, XENE	AI, Biotechnology, GLP1, healthcare, M&A, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The quarter saw several positive biotechnology clinical data readouts, a strong rebound in biotechnology funding, and an acceleration in M&A activity.	ACAD SS BFSA GR STM GR CIE SM BME LN	View
2025 Q3	Oct 21, 2025	Tourlite Capital Management	-2.0%	2.7%	ABUS, APG, FIP, FTAI, IONQ, NFE, OMAB, QBTS, QUBT, RGTI, ROIV, SBSW, TIC	Aviation, fundamentals, infrastructure, Long/Short, Quality, SPACs, Speculation, value	Fund operates as a long/short equity strategy capturing spread between long and short positions. Focuses on higher-quality businesses with positive earnings momentum on the long side while shorting companies with deteriorating fundamentals or unsustainable business models.		View
2024 Q3	Oct 21, 2024	Tourlite Capital Management	4.5%	13.8%	ABUS, APG, FTAI, ROIV, SBUX, SOC, ULTA, WMT	aerospace, consumer, Correlation, healthcare, industrials, Long/Short, technology, volatility	FTAI Aviation benefits from strong aerospace aftermarket tailwinds, with Boeing issues providing additional upside. The company exceeded Q2 expectations and raised 2026 EBITDA guidance by 25% to $1.25 billion. Significant valuation gap exists between FTAI and aerospace aftermarket peers.	APG ABUS ROIV FTAI SOC	View
2023 Q4	Jan 22, 2024	Biondo Investment Advisors	-	-	ABBV, ACLX, ARGX, AZN, BSX, CDTX, COO, HRTX, INSM, IONS, ISRG, JNJ, LLY, MASI, PFE, RDNT, ROIV, SYK, TMO, UNH, WAT, XENE	AI, Biotechnology, Diagnostics, GLP1, healthcare, Medical Devices, Pharmaceuticals	Strong stock selection in biotechnology contributed the vast majority of relative gains, with main drivers being argenx SE and Insmed Incorporated. The fund holds 31.8% in biotechnology companies and sees multiple secular growth opportunities in genomics, genetic testing, and genetic medicine.		View
2024 Q4	Feb 18, 2025	Tourlite Capital Management	0.4%	14.2%	FIP, FTAI, IMVT, LTCH, REAL, ROIV, SOC	aerospace, Biotechnology, consumer, energy, industrials, Long/Short, small cap, technology	FTAI Aviation emerged as a top performer with over 200% share price increase driven by aerospace aftermarket tailwinds and growing PMA parts business market share. The company announced FAA approval for its second PMA engine part and launched a Strategic Capital Initiative to acquire mid-life aircraft, tapping into a $30 billion market opportunity. Management projects this initiative will generate approximately $200 million in incremental annual aerospace EBITDA by 2026.	ROIV SOC LTCH FIP REAL FTAI	View
2023 Q4	Jan 26, 2024	Tourlite Capital Management	4.5%	13.8%	APG, ESPR, FC, FIP, FTAI, IMVT, KD, LTCH, PRM, PRVB, ROIV, SAN.PA	Aviation, Biotechnology, Event Driven, Long/Short, small caps, special situations	Fund initiated significant position in Roivant Sciences, a biotech company specializing in consolidating promising drug patents. Thesis based on cash value from asset sales, Immunovant stake, and pipeline upside potential. Also held Provention Bio which was acquired by Sanofi following FDA approval.	AFCG ROIV LTCH BKD FIP ESPR APG FTAI	View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Apr 28, 2026	Fund Letters	Tourlite Capital Management	Roivant Sciences	Health Care	Biotechnology	Bull	NASDAQ	Asymmetric, biotechnology, drug development, holding company, Patent Litigation, pipeline, Sum-of-parts, value creation	View Pitch
Apr 13, 2026	Fund Letters	Greenlight Capital	Roivant Sciences	Health Care	Biotechnology	Bull	NASDAQ	Atopic Dermatitis, Autoimmune Disease, biotechnology, COVID Vaccines, Immunology, Inflammation, Lipid Nanoparticles, Patent Royalties, psoriasis, share repurchase	View Pitch
Apr 13, 2026	Fund Letters	Tourlite Capital Management	Roivant Sciences	Health Care	Biotechnology	Bull	NASDAQ	biotechnology, Brepocitinib, cash position, Patent Litigation, Phase 3, royalties, share repurchase, Uveitis	View Pitch
Apr 13, 2026	Fund Letters	Penn Davis McFarland	Roivant Sciences Ltd.	Pharmaceuticals, Biotechnology & Life Sciences	Biotechnology	Bull	NASDAQ	Autoimmune, Biotech, Catalyst-Driven, holding company, M&A, negative enterprise value, Orphan drugs, Patent Litigation, tax-advantaged	View Pitch
Apr 13, 2026	Fund Letters	Tourlite Capital Management	Roivant Sciences	Health Care	Biotechnology	Bull	NASDAQ	biotechnology, capital allocation, drug development, Immunovant, Mosliciguat, pipeline, platform	View Pitch
Apr 13, 2026	Fund Letters	Tourlite Capital Management	Roivant	Health Care	Biotechnology	Bull	NASDAQ	Arbutus, biotechnology, Immunovant, LNP Litigation, Multiple Ways to Win, risk/reward, Stub Value, Sum-of-parts	View Pitch
Aug 13, 2025	Seeking Alpha	Out of Ignorance	Roivant Sciences	Health Care	Biotechnology	Neutral	NASDAQ	—	View Pitch

BSD Shareholders of ROIV

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: